SecBot SecBot
144 ·Filed Jun 15, 2026

RVMD

Revolution Medicines, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed5mo ago SEC0001462808-26-000002
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine insider sale for tax or diversification purposes with no material read-through. Monitor for any subsequent Form 4 filings to confirm execution, but no trading action is warranted based on this notice alone.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$156.58
T+0 close · Jun 15, 2026 · via day close
Latest settled
+29.87%
T+60 · $203.35
Vs SPY
+28.87%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 16 $156.58entry
  2. T+1 · 5mo ago +0.76%α +2.01% · $157.77
  3. T+5 · 5mo ago +8.26%α +10.49% · $169.51
  4. T+20 · 4mo ago +18.13%α +17.93% · $184.97
  5. T+60 · 2mo ago +29.87%α +28.87% · $203.35
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Officer Stephen Michael Kelsey filed a Form 144 notice of intent to sell 4,071 shares of Revolution Medicines common stock, valued at approximately $626,000. The shares were acquired through restricted stock unit grants in 2023-2025, and the sale appears to be a routine diversification or tax-related transaction. Given the negligible size relative to RVMD's $32.7B market cap, this filing carries no material signal for the stock.

Key Facts

  • Insider Stephen Michael Kelsey (officer) filed Form 144 to sell 4,071 shares of RVMD common stock.
  • Estimated market value of proposed sale: ~$626,405 based on filing date.
  • Shares were acquired via RSU grants on 03/01/2023, 03/01/2024, and 03/01/2025 for services rendered.
  • Prior sale of 4,302 shares occurred on 03/17/2026 for ~$427,965.
  • Filing represents intent to sell; actual sale may not occur.

Financial Impact

Proposed sale of 4,071 shares (~$626K) is immaterial relative to $32.7B market cap (0.002%).

dilution

Risk Factors

  • Insider may still execute the sale, but the amount is too small to signal negative sentiment.
  • No indication of broader insider selling pattern; prior 30-day insider activity totaled only $297K in sells.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
96% bullish (27 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001462808-26-000002
Document: 0001462808-26-000002-index.html0001462808-26-000002
Document: 0001462808-26-000002.txt0001462808-26-000002

US Market Status

Market Closed · Opens in 7h 52m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026